Fluoroquinolones, tuberculosis, and resistance

被引:324
作者
Ginsburg, AS [1 ]
Grosset, JH [1 ]
Bishai, WR [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Div Infect Dis, Ctr Tuberculosis Res, Baltimore, MD USA
关键词
D O I
10.1016/S1473-3099(03)00671-6
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Although the fluoroquinolones are presently used to treat tuberculosis primarily in cases involving resistance or intolerance to first-line antituberculosis therapy, these drugs are potential first-line agents and are under study for this indication. However, there is concern about the development of fluoroquinolone resistance in Mycobacterium tuberculosis, particularly when administered as monotherapy or as the only active agent in a failing multidrug regimen. Treatment failures as well as relapses have been documented under such conditions. With increasing numbers of fluoroquinolone prescriptions and the expanded use of these broad-spectrum agents for many infections, the selective pressure of fluoroquinolone use results in the ready emergence of fluoroquinolone resistance in a diversity of organisms, including M tuberculosis. Among M tuberculosis, resistance is emerging and may herald a significant future threat to the long-term clinical utility of fluoroquinolones. Discussion and education regarding appropriate use are necessary to preserve the effectiveness of this antibiotic class against the hazard of growing resistance.
引用
收藏
页码:432 / 442
页数:11
相关论文
共 164 条
[1]   Trends in bacterial resistance to fluoroquinolones [J].
Acar, JF ;
Goldstein, FW .
CLINICAL INFECTIOUS DISEASES, 1997, 24 :S67-S73
[2]   The clinical use of fluoroquinolones for the treatment of mycobacterial diseases [J].
Alangaden, GJ ;
Lerner, SA .
CLINICAL INFECTIOUS DISEASES, 1997, 25 (05) :1213-1221
[3]   CHARACTERIZATION OF FLUOROQUINOLONE-RESISTANT MUTANT STRAINS OF MYCOBACTERIUM-TUBERCULOSIS SELECTED IN THE LABORATORY AND ISOLATED FROM PATIENTS [J].
ALANGADEN, GJ ;
MANAVATHU, EK ;
VAKULENKO, SB ;
ZVONOK, NM ;
LERNER, SA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (08) :1700-1703
[4]   In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis [J].
Alvirez-Freites, EJ ;
Carter, JL ;
Cynamon, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :1022-1025
[5]  
American Thoracic Society, 1994, MONALDI ARCH CHEST D, V49, P327
[6]  
[Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
[7]  
[Anonymous], MMWR MORB MORTAL WKL
[8]   Resistance among Streptococcus pneumoniae:: Implications for drug selection [J].
Appelbaum, PC .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (12) :1613-1620
[9]   Relationship of isoniazid resistance to human immunodeficiency virus infection in patients with tuberculosis [J].
Asch, S ;
Knowles, L ;
Rai, A ;
Jones, BE ;
Pogoda, J .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (05) :1708-1710
[10]   Comparative tolerability of the newer fluoroquinolone antibacterials [J].
Ball, P ;
Mandell, L ;
Niki, Y ;
Tillotson, G .
DRUG SAFETY, 1999, 21 (05) :407-421